Dr. Reddy’s Laboratories Ltd. on Tuesday announced the launch of its novel patented molecule, Tegoprazan, in India under the brand name PCAB®, marking a major step forward in the treatment of acid-related gastrointestinal diseases.
Tegoprazan, a next-generation potassium-competitive acid blocker (P-CAB), is indicated for acid peptic diseases (APD) such as erosive and non-erosive gastroesophageal reflux disease (GERD/NERD) and gastric ulcers. According to the company, the drug ensures a fast onset of action and prolonged gastric pH control, potentially offering significant clinical benefits in APD management.
India has one of the highest burdens of APD globally, with recent data showing that nearly 38% of the population is affected. In a multinational trial conducted across India, South Africa, and Russia, 99% of GERD patients in the Tegoprazan arm achieved endoscopic healing by the eighth week. The drug has already been approved in 21 countries, including South Korea and China, and has completed Phase-III trials in the United States.
The launch follows Dr. Reddy’s exclusive 2022 partnership with South Korea-based HK inno.N Corporation to commercialize Tegoprazan in India and select emerging markets.
M.V. Ramana, CEO of Branded Markets (India & Emerging Markets) at Dr. Reddy’s, said:
“We are happy to launch Tegoprazan in India, reinforcing our commitment to innovation in gastrointestinal treatment. This molecule bridges a critical gap in acid peptic disease management and improves patient outcomes.”
Dal-Won Kwak, CEO of HK inno.N, added that the Indian market presents an important opportunity for Tegoprazan to establish itself as a leading innovative therapy within the P-CAB class.
